Biopharma deal activity climbed in early 2025, reaching $37.38 billion in the first two months, up from $35.66 billion a year ...

Post-merger integration is key to M&A success, ensuring operational continuity, synergy realisation, and risk management.

Pharma with 4,314 puts trading, or 4x expected. Most active are Mar-25 38.5 puts and Apr-25 37 puts, with total ...

GSK acquired Zejula as part of its $5.1 billion takeover of Tesaro in 2018, along with other oncology drug candidates, including latecomer PD-1 inhibitor Jemperli (dostarlimab) and others ...

The US Food and Drug Administration (FDA) has accepted for review GSK’s Biologics License Application for depemokimab.

GSK's consumer health spinout Haleon started trading on the London Stock Exchange this morning, making its debut with a price of 330 pence and a market valuation of around £31 billion ($37 billion).

Shares of GSK plc (NYSE:GSK – Get Free Report) have been given an average rating of “Moderate Buy” by the ten brokerages that are presently covering the firm, Marketbeat.com reports.

Check Out Our Latest Research Report on GSK GSK Price Performance GSK opened at $37.33 on Friday. The company has a current ratio of 0.78, a quick ratio of 0.52 and a debt-to-equity ratio of 1.12 ...

UK drugmaker GSK was one of the companies spending money away from the UK this month, agreeing to acquire US-based biotech IDRx for $1.15bn to bolster its oncology portfolio. The deal follows GSK’s ...

Of 12 evaluable patients, four experienced a partial response, translating to a 33% response rate, while one patient achieved a complete response with no detectable cancer for over 15 months. By ...